Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
May 5, 2026 updated by: Marie Bleakley, Fred Hutchinson Cancer Center
A Phase II Study Evaluating Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors for Prevention of GVHD
This phase II trial is for patients with acute lymphocytic leukemia, acute myeloid leukemia, myelodysplastic syndrome or chronic myeloid leukemia who have been referred for a peripheral blood stem cell transplantation to treat their cancer.
In these transplants, chemotherapy and total-body radiotherapy ('conditioning') are used to kill residual leukemia cells and the patient's normal blood cells, especially immune cells that could reject the donor cells.
Following the chemo/radiotherapy, blood stem cells from the donor are infused.
These stem cells will grow and eventually replace the patient's original blood system, including red cells that carry oxygen to our tissues, platelets that stop bleeding from damaged vessels, and multiple types of immune-system white blood cells that fight infections.
Mature donor immune cells, especially a type of immune cell called T lymphocytes (or T cells) are transferred along with these blood-forming stem cells.
T cells are a major part of the curative power of transplantation because they can attack leukemia cells that have survived the chemo/radiation therapy and also help to fight infections after transplantation.
However, donor T cells can also attack a patient's healthy tissues in an often-dangerous condition known as Graft-Versus-Host-Disease (GVHD).
Drugs that suppress immune cells are used to decrease the severity of GVHD; however, they are incompletely effective and prolonged immunosuppression used to prevent and treat GVHD significantly increases the risk of serious infections.
Removing all donor T cells from the transplant graft can prevent GVHD, but doing so also profoundly delays infection-fighting immune reconstitution and eliminates the possibility that donor immune cells will kill residual leukemia cells.
Work in animal models found that depleting a type of T cell, called naïve T cells or T cells that have never responded to an infection, can diminish GVHD while at least in part preserving some of the benefits of donor T cells including resistance to infection and the ability to kill leukemia cells.
This clinical trial studies how well the selective removal of naïve T cells works in preventing GVHD after peripheral blood stem cell transplants.
This study will include patients conditioned with high or medium intensity chemo/radiotherapy who can receive donor grafts from related or unrelated donors.
Study Overview
Status
Status
Completed
Conditions
Conditions
- Lymphoblastic Lymphoma
- Childhood Acute Myeloid Leukemia in Remission
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Myelodysplastic Syndrome With Excess Blasts
- Childhood Acute Lymphoblastic Leukemia in Remission
- Recurrent Childhood Acute Lymphoblastic Leukemia
- Recurrent Childhood Acute Myeloid Leukemia
- Blastic Plasmacytoid Dendritic Cell Neoplasm
- Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Recurrent Acute Lymphoblastic Leukemia
- Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Refractory Acute Lymphoblastic Leukemia
- Myelodysplastic Syndrome With Excess Blasts-2
- Acute Leukemia of Ambiguous Lineage
- Acute Undifferentiated Leukemia
- Acute Biphenotypic Leukemia
- Allogeneic Hematopoietic Stem Cell Transplant Recipient
- Acute Myeloid Leukemia in Remission
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Acute Lymphoblastic Leukemia in Remission
- Donor
- Myelodysplastic Syndrome With Excess Blasts-1
Intervention / Treatment
Intervention / Treatment
- Other: Laboratory Biomarker Analysis
- Drug: Cyclophosphamide
- Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
- Drug: Methotrexate
- Radiation: Total-Body Irradiation
- Drug: Fludarabine Phosphate
- Drug: Tacrolimus
- Drug: Thiotepa
- Drug: Mycophenolate Mofetil
- Procedure: Peripheral Blood Stem Cell Transplantation
- Procedure: Peripheral Blood Stem Cell Transplantation
Detailed Description
OUTLINE: Patients are assigned to 1 of 4 treatment arms.
CONDITIONING:
ARMS A AND C (high-intensity myeloablative conditioning): Patients undergo total body irradiation twice daily (BID) on days -10 to -7. Patients also receive thiotepa intravenously (IV) over 4 hours on days -6 and -5 and fludarabine phosphate IV over 30 minutes on days -6 to -2.
ARMS B AND D (lower-intensity myeloablative conditioning): Patients receive cyclophosphamide IV over 1 hour on day -6, fludarabine phosphate IV over 30 minutes on days -6 to -2, and thiotepa IV over 4 hours on days -5 and -4. Patients also undergo total body irradiation once daily (QD) on days -2 and -1.
TRANSPLANT: In all arms, patients undergo allogeneic HSCT with granulocyte colony-stimulating factor (GCSF)-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0.
GVHD PROPHYLAXIS:
ARMS A AND C: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or orally (PO) (BID if given PO) for 50 days with taper in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.
ARMS B AND D: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days and mycophenolate mofetil IV and PO every 8 hours on days -3 to approximately day 30, with or without taper at the discretion of the treating physician. Mycophenolate mofetil should be continued or resumed after day 30 if donor chimerism is low, after discussion with the principal investigator.
After completion of study treatment, patients are followed up at 80-100 days, 360 days, and then yearly for up to 5 years.
Study Type
Study Type
Interventional
Enrollment (Actual)
Enrollment
84
Phase
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15232
- University of Pittsburgh Cancer Institute (UPCI)
-
-
Washington
-
Seattle, Washington, United States, 98109
- Fred Hutch/University of Washington Cancer Consortium
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
No older than 60 years (Child, Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
Patients who are considered appropriate candidates for allogeneic hematopoietic stem cell transplantation and have one of the following diagnoses:
- Acute lymphocytic leukemia in first or subsequent remission
- Acute myeloid leukemia in first or subsequent remission
- Acute lymphocytic leukemia in relapse or primary refractory disease with a circulating blast count of no more than 10,000/mm^3 (Arms A or C only)
- Acute myeloid leukemia in relapse or primary refractory disease with a circulating blast count of no more than 10,000/mm^3 (Arms A or C only)
- Refractory anemia with excess blasts (RAEB-1 and RAEB-2) (if the patient has received previous induction chemotherapy within 60 days)
- Chronic myelogenous leukemia with a history of accelerated phase or blast crisis (if the patient has received at least one course of induction chemotherapy)
- Other acute leukemia or related neoplasm (including but not limited to 'biphenotypic', 'undifferentiated' or 'ambiguous lineage' acute leukemia, blastic plasmacytoid dendritic cell neoplasm or lymphoblastic lymphoma)
- Patients 0-49 years old will be enrolled in Arm A or C (high-intensity)
- Patients 50-60 years old will be enrolled in Arm B or D (lower intensity); patients eligible for Arms B or D also include those who have received previous allogeneic HCT, or who have co-morbid conditions rendering them unsuitable for high-dose conditioning, determined in consultation with the principal investigator
- Patient with a HLA-matched (HLA-A, B, C, and DR beta 1 [DRB1] molecularly matched) unrelated donor or related donor capable of donating PBSC
- DONOR INCLUSION:
- HLA-matched related donors >= 18 years and capable and willing to donate PBSC (Arms A and B)
- HLA-matched unrelated donors (HLA-A, B, C, and DRB1 matched based on high-resolution typing) capable and willing to donate PBSC (Arms C and D)
Exclusion Criteria:
- Patients with central nervous system (CNS) involvement refractory to intrathecal chemotherapy and/or standard cranial-spinal radiation
- Patients on other experimental protocols for prevention of acute GVHD
- Patient weight >= 100 kg; patients >= 70 kg with MUDs must be discussed with the principal investigator
- Patients who are human immunodeficiency virus positive (HIV+)
- Patients with uncontrolled infections for whom myeloablative HCT is considered contraindicated by the consulting infectious disease physician (upper respiratory tract viral infection does not constitute an uncontrolled infection in this context)
- Patients with organ dysfunction
- ARM A OR C EXCLUSION:
- Creatinine > 1.5 mg/dl at the present time; patients with a known history of creatinine > 1.5 mg/dl must have a current estimated creatinine clearance of > 40 ml/min
- Cardiac ejection fraction < 45%
- Diffusing capacity of the lung for carbon monoxide (DLCO) corrected < 60%; patients who are unable to perform pulmonary function tests (for example, due to young age and/or developmental status) will be excluded if the oxygen (O2) saturation is < 92% on room air
- Liver function abnormality; patients who have liver function tests (LFTs) (including total bilirubin, aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) >= twice the upper limit of normal should be evaluated by a gastrointestinal (GI) physician; unless there is a clear precipitating factor (such as an azole, methotrexate, Bactrim or another drug); if the GI physician considers that HCT on the high-intensity arms of protocol is contraindicated for that patient the patient may be considered for treatment on the lower intensity arm of the protocol or excluded from the protocol; patients with Gilbert's syndrome and no other known liver function abnormality and patients with reversible drug-related transaminitis do not necessarily require GI consultation and may be included on the high-intensity arms of the protocol
- ARM B OR D EXCLUSION:
- Creatinine > 2.0 mg/dl at the present time; patients with a known history of creatinine > 1.5 mg/dl must have a current estimated creatinine clearance > 40 ml/min
- Cardiac ejection fraction < 35%
- DLCO corrected < 50%; patients who are unable to perform pulmonary function tests (for example, due to young age and/or developmental status) will be excluded if the O2 saturation is < 92% on room air; patients with a DLCO 50-60% must also have a partial pressure of oxygen (pO2) of > 80 mmHg
- Liver function abnormality; patients who have LFTs >= twice the upper limit of normal should be evaluated by a GI physician unless there is a clear precipitating factor (such as an azole, methotrexate, Bactrim or another drug); patients with fulminant liver failure, cirrhosis with evidence of portal hypertension or bridging fibrosis, alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices, hepatic encephalopathy, or correctable hepatic synthetic dysfunction evidenced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin > 3 mg/dL, and symptomatic biliary disease will be excluded
- Patients will be excluded from Arms A and C if they have received a previous myeloablative transplant; patients who have received a prior HCT at least 6 months prior may be considered for inclusion on Arms B or D after discussion with the principal investigator (PI)
- Patients with a life expectancy < 3 months from co-existing disease other than the leukemia or RAEB
- Patients who are pregnant or breast-feeding
- Fertile patients of child bearing age unwilling to use contraception during and for 12 months post-transplant
- Patients with a significant other medical conditions that would make them unsuitable for transplant
- Patients with a known hypersensitivity to tacrolimus, methotrexate (Arm A or C) or MMF (Arm B or D)
- DONOR EXCLUSION:
- Donors who are HIV-1, HIV-2, human T-lymphotropic virus (HTLV)-1, HTLV-2 seropositive or with active hepatitis B or hepatitis C virus infection
- Donors who fail eligibility requirements for donation of cells or tissue for donation of a Human Cell and Tissue Products (HCT/P) will be excluded unless use of the cells complies urgent medical need or allogeneic use in a first-degree or second-degree relative
- Unrelated donors donating outside of the United States of America (USA)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
4
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Arm A (MRD)
HIGH-INTENSITY MYELOABLATIVE CONDITIONING: Patients undergo total body irradiation BID on days -10 to -7. Patients also receive thiotepa IV over 4 hours on days -6 and -5 and fludarabine phosphate IV over 30 minutes on days -6 to -2. TRANSPLANT: In all arms, patients undergo allogeneic HSCT with GCSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0. GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days with taper in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11. |
Correlative studies
Given IV
Other Names:
Undergo allogeneic HSCT
Other Names:
Given IV
Other Names:
Undergo TBI
Other Names:
Given IV
Other Names:
Given IV or PO
Other Names:
Given IV
Other Names:
Undergo PBSCT with GCSF-mobilized CD34-enriched PBSC
Other Names:
Undergo PBSCT with CD45RA-depleted cells
Other Names:
|
|
Experimental: Arm B (MRD)
LOWER-INTENSITY MYELOABLATIVE CONDITIONING: Patients receive cyclophosphamide IV over 1 hour on day -6, fludarabine phosphate IV over 30 minutes on days -6 to -2, and thiotepa IV over 4 hours on days -5 and -4. Patients also undergo total body irradiation QD on days -2 and -1. TRANSPLANT: In all arms, patients undergo allogeneic HSCT with GCSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0. GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days and mycophenolate mofetil IV and PO every 8 hours on day -3 to approximately day 30, with or without taper at the discretion of the treating physician. Mycophenolate mofetil should be continued or resumed after day 30 if donor chimerism is low, after discussion with the Principal Investigator. |
Correlative studies
Given IV
Other Names:
Undergo allogeneic HSCT
Other Names:
Undergo TBI
Other Names:
Given IV
Other Names:
Given IV or PO
Other Names:
Given IV
Other Names:
Given IV and PO
Other Names:
Undergo PBSCT with GCSF-mobilized CD34-enriched PBSC
Other Names:
Undergo PBSCT with CD45RA-depleted cells
Other Names:
|
|
Experimental: Arm C (MUD)
HIGH-INTENSITY MYELOABLATIVE CONDITIONING: Patients undergo total body irradiation BID on days -10 to -7. Patients also receive thiotepa IV over 4 hours on days -6 and -5 and fludarabine phosphate IV over 30 minutes on days -6 to -2. TRANSPLANT: In all arms, patients undergo allogeneic HSCT with G-CSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0. GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days with taper in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11. |
Correlative studies
Given IV
Other Names:
Undergo allogeneic HSCT
Other Names:
Given IV
Other Names:
Undergo TBI
Other Names:
Given IV
Other Names:
Given IV or PO
Other Names:
Given IV
Other Names:
Undergo PBSCT with GCSF-mobilized CD34-enriched PBSC
Other Names:
Undergo PBSCT with CD45RA-depleted cells
Other Names:
|
|
Experimental: Arm D (MUD)
LOWER-INTENSITY MYELOABLATIVE CONDITIONING: Patients receive cyclophosphamide IV over 1 hour on day -6, fludarabine phosphate IV over 30 minutes on days -6 to -2, and thiotepa IV over 4 hours on days -5 and -4. Patients also undergo total body irradiation QD on days -2 and -1. TRANSPLANT: In all arms, patients undergo allogeneic HSCT with G-CSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0. GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days and mycophenolate mofetil IV and PO every 8 hours on day -3 to approximately day 30, with or without taper at the discretion of the treating physician. Mycophenolate mofetil should be continued or resumed after day 30 if donor chimerism is low, after discussion with the Principal Investigator. |
Correlative studies
Given IV
Other Names:
Undergo allogeneic HSCT
Other Names:
Given IV
Other Names:
Given IV or PO
Other Names:
Given IV
Other Names:
Given IV and PO
Other Names:
Undergo PBSCT with GCSF-mobilized CD34-enriched PBSC
Other Names:
Undergo PBSCT with CD45RA-depleted cells
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Chronic GVHD
Time Frame: Up to 5 years post-transplant
|
Occurrence of chronic graft-versus-host disease (GHVD), defined operationally as the occurrence of compatible symptoms meeting National Institutes of Health criteria and requiring systemic pharmacological immunosuppression.
|
Up to 5 years post-transplant
|
|
Time to Completion of Prednisone
Time Frame: Up to 5 years post-transplant
|
Measure the number of days to discontinuation of prednisone in recipients of CD45RA+ T cell-depleted PBSCT by arm.
Possible outcomes range from no systemic immunosuppression (best outcome) to 5 years on immunosuppression (poor outcome)
|
Up to 5 years post-transplant
|
|
Time to Completion of All Immunosuppression
Time Frame: Up to 5 years post-transplant
|
Measure the number of days to discontinuation of all immunosuppression in recipients of CD45RA+ T cell-depleted PBSCT by arm.
Possible outcomes range from no systemic immunosuppression (best outcome) to 5 years on immunosuppression (poor outcome)
|
Up to 5 years post-transplant
|
|
Requirement of Immunosuppression at 2 Years After Transplant
Time Frame: At 2 years post transplant
|
Number of patients requiring immunosuppression 2 years after transplant.
|
At 2 years post transplant
|
|
Acute GVHD
Time Frame: Through day 100 post-transplant
|
Presence of acute graft-versus-host disease (GVHD) grades II-IV, defined operationally as the occurrence of compatible symptoms or signs in the skin, gastrointestinal tract, or liver, in patients who received Naive t cell depleted PBSCT.
Staging and grading are found on page 8 of the JCO supplement (Bleakley et al., 2022, original references Glucksberg et all, 1974, Przepiorka et all, 1995 ) with higher grade indicating worse outcomes.
|
Through day 100 post-transplant
|
|
Graft Failure
Time Frame: Up to 5 years post-transplant
|
Defined operationally as failure to reach an absolute neutrophil count (ANC) of > 500/ul for 3 consecutive days by day 28 or irreversible decrease in ANC to < 100 after an established donor graft.
|
Up to 5 years post-transplant
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Transplant Related Mortality by Day 100
Time Frame: Through day 100 post-transplant
|
Defined as mortality in any patient for whom there has not been a diagnosis of relapse.
|
Through day 100 post-transplant
|
|
Relapse
Time Frame: Up to 5 years post-transplant
|
Defined by the presence of malignant cells in marrow, peripheral blood, or extramedullary sites by histopathology.
|
Up to 5 years post-transplant
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Other Immunosuppressive Agents
Time Frame: Up to 5 years
|
Use of additional immune suppressive agents other than first line therapy (prednisone and tacrolimus/cyclosporine)
|
Up to 5 years
|
|
aGVHD Management - Secondary
Time Frame: Up to day 100
|
Requirement for secondary systemic therapy for acute graft-versus-host disease (GVHD) management
|
Up to day 100
|
|
Engraftment - ANC >500/uL
Time Frame: Through day 100 post-transplant
|
Time to absolute neutrophil count (ANC) of > 500/uL on the first of three consecutive days
|
Through day 100 post-transplant
|
|
Engraftment - ANC <1,000/uL
Time Frame: through Day 100 post-transplant
|
Time to absolute neutrophil count (ANC) of > 1,000/uL on the first of three consecutive test results
|
through Day 100 post-transplant
|
|
Platelet Engraftment
Time Frame: Through day 100 post-transplant
|
Time to platelet count > 20,000/uL for 3 days without transfusion
|
Through day 100 post-transplant
|
|
Platelet Engraftment - 50,000/uL
Time Frame: Through day 100 post-transplant
|
Time to platelet count > 50,000/uL for 3 days without transfusion
|
Through day 100 post-transplant
|
|
Chimerism Analysis
Time Frame: Up to 360 days
|
Will be analyzed from peripheral blood or marrow.
|
Up to 360 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Marie Bleakley, Fred Hutch/University of Washington Cancer Consortium
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
Study Start
March 23, 2015
Primary Completion (Actual)
Primary Completion
April 1, 2025
Study Completion (Actual)
Study Completion
May 1, 2025
Study Registration Dates
First Submitted
First Submitted
August 18, 2014
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
August 18, 2014
First Posted (Estimated)
First Posted
August 20, 2014
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
June 1, 2026
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
May 5, 2026
Last Verified
Last Verified
May 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Site
- Neoplasms
- Chronic Disease
- Disease Attributes
- Immune System Diseases
- Neoplasms by Histologic Type
- Hematologic Diseases
- Neoplastic Processes
- Skin Diseases
- Lymphatic Diseases
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Lymphoma
- Leukemia, Myeloid
- Bone Marrow Diseases
- Anemia
- Leukemia, Lymphoid
- Leukemia
- Skin Neoplasms
- Myelodysplastic Syndromes
- Anemia, Refractory
- Myeloproliferative Disorders
- Hematologic Neoplasms
- Histiocytic Disorders, Malignant
- Cell Transformation, Neoplastic
- Carcinogenesis
- Pathological Conditions, Signs and Symptoms
- Skin and Connective Tissue Diseases
- Hemic and Lymphatic Diseases
- Leukemia, Myeloid, Acute
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Anemia, Refractory, with Excess of Blasts
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Blast Crisis
- Leukemia, Biphenotypic, Acute
- Leukemia, Myeloid, Accelerated Phase
- Blastic Plasmacytoid Dendritic Cell Neoplasm
- Organic Chemicals
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Investigative Techniques
- Therapeutics
- Fatty Acids
- Lipids
- Surgical Procedures, Operative
- Hydrocarbons
- Acids, Acyclic
- Carboxylic Acids
- Transplantation
- Macrolides
- Lactones
- Phosphoramide Mustards
- Nitrogen Mustard Compounds
- Mustard Compounds
- Hydrocarbons, Halogenated
- Phosphoramides
- Organophosphorus Compounds
- Pterins
- Pteridines
- Aminopterin
- Radiotherapy
- Cell Transplantation
- Cell- and Tissue-Based Therapy
- Biological Therapy
- Triethylenephosphoramide
- Aziridines
- Azirines
- Caproates
- Stem Cell Transplantation
- Hematopoietic Stem Cell Transplantation
- Methotrexate
- Cyclophosphamide
- Mycophenolic Acid
- Tacrolimus
- Thiotepa
- fludarabine phosphate
- Whole-Body Irradiation
- merphos
- Peripheral Blood Stem Cell Transplantation
Other Study ID Numbers
Other Study ID Numbers
- 2684.00 (Other Identifier: Fred Hutch/University of Washington Cancer Consortium)
- R01HL121568 (U.S. NIH Grant/Contract)
- 2P01CA018029 (U.S. NIH Grant/Contract)
- NCI-2014-01301 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- RG9214012 (Other Identifier: Fred Hutch/University of Washington Cancer Consortium)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoblastic Lymphoma
-
NCT02538926WithdrawnRecurrent Adult Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Recurrent B Lymphoblastic Lymphoma | Refractory B Lymphoblastic Lymphoma | B Lymphoblastic Lymphoma | Recurrent T Lymphoblastic Leukemia/Lymphoma | Refractory T Lymphoblastic Lymphoma | T Acute Lymphoblastic Leukemia | T Lymphoblastic Lymphoma
-
NCT07175415Not yet recruitingAcute Lymphoblastic Leukemia | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
-
NCT02293109CompletedStage IV Adult Lymphoblastic Lymphoma | Contiguous Stage II Adult Lymphoblastic Lymphoma | Noncontiguous Stage II Adult Lymphoblastic Lymphoma | Stage I Adult Lymphoblastic Lymphoma | Stage III Adult Lymphoblastic Lymphoma | Untreated Adult Acute Lymphoblastic Leukemia
-
NCT05751044RecruitingAcute Lymphoblastic Leukemia | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
-
NCT05740449WithdrawnAcute Lymphoblastic Leukemia, in Relapse | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
-
NCT05745714RecruitingAcute Lymphoblastic Leukemia, in Relapse | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
-
NCT05658640RecruitingAcute Lymphoblastic Leukemia, in Relapse | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
-
NCT01658007TerminatedRecurrent Adult Lymphoblastic Lymphoma | Refractory Acute Lymphoblastic Leukemia | Refractory Lymphoblastic Lymphoma | Relapsed Lymphoblastic Leukemia
-
NCT05885464Active, not recruitingLymphoblastic Lymphoma | Lymphoblastic Leukemia | T-Cell Lymphoblastic Leukemia/Lymphoma
-
NCT03504644Active, not recruitingRecurrent Adult Lymphoblastic Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Recurrent B Lymphoblastic Lymphoma | Refractory B Lymphoblastic Lymphoma | Refractory T Acute Lymphoblastic Leukemia | Refractory T Lymphoblastic Lymphoma | Recurrent T Acute Lymphoblastic Leukemia | Recurrent T Lymphoblastic Lymphoma
Clinical Trials on Laboratory Biomarker Analysis
-
NCT01298414Completed
-
NCT00003861Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic Leukemia
-
NCT00482352CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic Leukemia
-
NCT00897507CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic Leukemia
-
NCT01517971Completed
-
NCT01503619Completed
-
NCT01642095WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney Neoplasm
-
NCT00899145WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier
-
NCT01493817CompletedWilms Tumor and Other Childhood Kidney Tumors
-
NCT01642121CompletedChildhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia Without Maturation (M1) | Childhood Acute Myelomonocytic Leukemia (M4) | Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies